2017 ASCO Annual Meeting

Tony Mok, MD, Chinese University of Hong Kong, presenting Abstract LBA9007, Dacomitinib versus gefitinib for the first-line treatment of advanced EGFR mutation positive non-small cell lung cancer (ARCHER 1050): A randomized, open-label phase 3 trial, during Monday Press Briefing

Chicago, IL - 2017 ASCO Annual Meeting - Tony Mok, MD, Chinese University of Hong Kong, presenting Abstract LBA9007, Dacomitinib versus gefitinib for the first-line treatment of advanced EGFR mutation positive non-small cell lung cancer (ARCHER 1050): A randomized, open-label phase 3 trial, during Monday's Press Briefing at the American Society of Clinical Oncology (ASCO) Annual Meeting here today, Monday, June 5, 2017. Approximately 40,000 physicians, researchers, and healthcare professionals from over 100 countries are attending the 53rd Annual Meeting, which is being held at McCormick Place. The ASCO Annual Meeting highlights the latest findings in all major areas of oncology, from basic to clinical and epidemiological studies. Photo by © ASCO/Scott Morgan 2017 Technical Questions: todd@medmeetingimages.com; ASCO Contact: photos@asco.org